Form 4: Actuate Therapeutics Director Receives Stock Options

Director Jason A. Keyes was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Director Jason A. Keyes acquired 15,000 stock options in Actuate Therapeutics, Inc. (ACTU).
• The options have an exercise price of $2.42 per share.
• The grant date for these options is May 21, 2026.
• The options are scheduled to expire on May 21, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $2.42 exercise price.

Future Outlook

The options vest in full on the first anniversary of the grant date (May 21, 2027).

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The 10-year expiration term is standard for executive and director equity incentive plans.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 15,000 options on May 21, 2027.

Key Dates

Keywords

Actuate Therapeutics, ACTU, Form 4, Insider Trading, Stock Options, Director Compensation